Compare Agnico Eagle Mines Ltd (AEM) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Eli Lilly And Co — how do they compare? Agnico Eagle Mines Ltd trades at $183.63 (market cap $91.28B), while Eli Lilly And Co trades at $1,214.89 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 12.1× Agnico Eagle Mines Ltd's market cap, and Agnico Eagle Mines Ltd pays the higher dividend (1%). Which is the better fit depends on your goals.
| AEM | LLY | |
|---|---|---|
Market Cap | $91.28B | $1.10T |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $1.24K |
52-Week Low | $130.23 | $639.43 |
Enterprise Value | $88.12B | $1.14T |
Dividend Yield | 1% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEM trades at $178.82, up 6.49% in the past 24 hours, reflecting strong momentum driven by record free cash flow and consistent earnings beats. The stock exhibits bullish technical signals with support at $177 and resistance at $181, while fundamentals show robust revenue growth to $11.91B in 2025 and a net income margin of 40.44%. Recent news highlights operational strength and gold price tailwinds.
Outlook remains positive with a consensus price target of $219.63, though risks include production costs and gold volatility. Analyst sentiment is strongly bullish with 21 buy ratings, supporting upside potential if execution continues.
Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.
Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
